AstraZeneca's imfinzi cuts death risk by 22% in early gastric cancer

OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy

Glenmark Pharmaceuticals USA to launch Ropivacaine Hydrochloride Injection USP

Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA

Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients

Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile

Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC

Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab

Integris Medtech files DRHP with SEBI for IPO

The company plans to use the funds raised from the net proceeds to repay or prepay certain loans

Coveris and SABIC pioneer closed-loop recycling for medical packaging

The initiative successfully demonstrates that used medical plastic packaging can be recycled and transformed back into new, contact-sensitive medical packaging

WHO and OneSight EssilorLuxottica partner to expand vision care in Karnataka

WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030

Nanavati Max, Uzbekistan’s NVRH forge alliance to advance healthcare and training

FDA approves Roche’s Tecentriq + lurbinectedin as first-line maintenance therapy for lung cancer

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study

AbbVie’s Natrelle awarded supplier agreement from Vizient

This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market